Compare ASTRAZENECA PHARMA with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs SUN PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA SUN PHARMA ASTRAZENECA PHARMA/
SUN PHARMA
 
P/E (TTM) x 125.8 80.4 156.5% View Chart
P/BV x 38.5 3.4 1,123.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   SUN PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
SUN PHARMA
Mar-20
ASTRAZENECA PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278484 264.0%   
Low Rs883315 280.0%   
Sales per share (Unadj.) Rs228.4136.9 166.9%  
Earnings per share (Unadj.) Rs10.417.5 59.4%  
Cash flow per share (Unadj.) Rs16.326.0 62.5%  
Dividends per share (Unadj.) Rs04.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs98.8188.7 52.4%  
Shares outstanding (eoy) m25.002,399.26 1.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.9 162.0%   
Avg P/E ratio x104.222.9 455.1%  
P/CF ratio (eoy) x66.415.4 432.3%  
Price / Book Value ratio x10.92.1 516.3%  
Dividend payout %022.9 0.0%   
Avg Mkt Cap Rs m27,008958,864 2.8%   
No. of employees `0001.417.8 7.6%   
Total wages/salary Rs m1,53563,624 2.4%   
Avg. sales/employee Rs Th4,210.918,490.6 22.8%   
Avg. wages/employee Rs Th1,132.23,582.6 31.6%   
Avg. net profit/employee Rs Th191.12,357.6 8.1%   
INCOME DATA
Net Sales Rs m5,710328,375 1.7%  
Other income Rs m1236,360 1.9%   
Total revenues Rs m5,833334,735 1.7%   
Gross profit Rs m46369,898 0.7%  
Depreciation Rs m14720,528 0.7%   
Interest Rs m03,027 0.0%   
Profit before tax Rs m43852,702 0.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-2,606 0.0%   
Tax Rs m1798,228 2.2%   
Profit after tax Rs m25941,868 0.6%  
Gross profit margin %8.121.3 38.1%  
Effective tax rate %40.815.6 261.6%   
Net profit margin %4.512.8 35.6%  
BALANCE SHEET DATA
Current assets Rs m3,209316,542 1.0%   
Current liabilities Rs m2,070157,064 1.3%   
Net working cap to sales %20.048.6 41.1%  
Current ratio x1.62.0 76.9%  
Inventory Days Days7288 82.6%  
Debtors Days Days35105 33.3%  
Net fixed assets Rs m790243,102 0.3%   
Share capital Rs m502,399 2.1%   
"Free" reserves Rs m2,419450,245 0.5%   
Net worth Rs m2,469452,645 0.5%   
Long term debt Rs m020,289 0.0%   
Total assets Rs m4,605682,525 0.7%  
Interest coverage xNM18.4-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.5 257.7%   
Return on assets %5.66.6 85.5%  
Return on equity %10.59.2 113.4%  
Return on capital %17.711.2 157.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30074,219 0.4%   
Fx outflow Rs m2,01527,964 7.2%   
Net fx Rs m-1,71546,255 -3.7%   
CASH FLOW
From Operations Rs m8865,548 0.1%  
From Investments Rs m-94-25,888 0.4%  
From Financial Activity Rs mNA-57,151 0.0%  
Net Cashflow Rs m-6-13,857 0.0%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 5.1 5.8%  
FIIs % 15.7 23.0 68.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 8.3 109.6%  
Shareholders   12,856 133,026 9.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   PFIZER  GSK PHARMA  FRESENIUS KABI ONCO.  WYETH  ABBOTT INDIA  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

SGX Nifty Up 60 Points, 6 Reasons Behind the Stock Market Crash, HDFC Bank Q4FY21 Results, and Buzzing Stocks Today(Pre-Open)

Indian share markets nosedived and registered sharp losses in yesterday's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Warning About Bubbles(Fast Profits Daily)

Apr 16, 2021

Those who don't learn from financial history are doomed to lose their money.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Apr 20, 2021 09:20 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - WYETH COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS